Brigatinib

BreastfeedingPediatric

FDA APPROVAL DATE: 04/28/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Boceprevir, Carbamazepine, Clarithromycin, Cobicistat, Conivaptan, CYP3A substrates and strong CYP3A inducers or inhibitors, Grapefruit Juice, Hormonal contraceptives, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nelfinavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Voriconazole

PREGNANCY CATEGORY: N/A
May cause fetal toxicity based on findings in animal studies

Our database has 44 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top